KRAS and lung carcinoma: Importantly, KRA-533 significantly reduces tumor burden in the lungs of both LSL-KRASG12D and KL mice, leading to prolonged survival compared to the untreated control group, suggesting that KRA-533 has potential to improve the prognosis of mutant KRAS driven lung cancer.